Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Graft-Versus-Host Disease Therapy
New graft-versus-host disease therapy study findings recently were reported by F.M. Marty and co-researchers
August 14th, 2007
Data detailed in "Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis" have been presented. "Sirolimus-based immunosuppressive regimens in organ transplantation have been associated with a lower than expected incidence of cytomegalovirus (CMV) disease. Whether sirolimus has a similar effect on CMV reactivation after allogeneic hematopoietic stem cell transplantation (HSCT) is not known," scientists writing in the journal Blood report. "We evaluated 606 patients who underwent HSCT between April 2000 and June 2004 to identify risk factors for...
Source: Virus Weekly (2007-08-14)
|
